The microbe is mightier than the market

Appointing an economist to save us from superbugs might seem odd but, as with many problems, money is at the root of it


Some mocked David Cameron for selecting a money man rather than a medic to head the Government's antibiotics taskforce. On the surface giving the job to Jim O'Neill, the former chief economist at the investment bankers Goldman Sachs, does seem eccentric.

Drugs which have saved millions of lives over the past century are becoming steadily less effective. Superbugs are developing a resistance to the medicines. Antibiotics, which turned once-fatal diseases into trivial inconveniences, are beginning to be outsmarted by evolving microbes. These resistant superbugs killed 5,000 people in the UK last year – and five times more in Europe, 160 times as many in China and 200 times that number in the United States.

But there is more to this than biochemistry. There are cultural issues too. The problem is "pushy patients" demanding antibiotics they don't need, says England's chief medical officer. Our litigation-mad society makes doctors prescribe unnecessary drugs for fear that they will be sued, other medics say. Or it is ignorant patients who – as Alexander Fleming predicted when he discovered the first antibiotic, penicillin, in 1928 – have provoked bacterial resistance by failing to complete the prescribed course once they start to feel better.

Yet economics raises its myopic head too. Some 70 per cent of antibiotic doses in the United States are given prophylactically to farm animals, to keep them healthy in overcrowded conditions, or to promote tissue growth. Antibiotic growth promoters have been banned in the European Union since 2006 and yet vets in the UK claim they see antibiotics used "willy-nilly" on farms all the time as a preventative measure rather than a treatment.

There is, however, an even bigger financial issue. Germs are developing resistance faster than new antibiotics are being developed mainly because no new antibiotics are being developed at all. That is because there is no money in it for the drug companies. It is this economic model which is the real villain in the erosion of the effectiveness of antibiotics. That is why O'Neill is the right man for the job – if, that is, he can set aside his free-market ideology.

The big problem in the war against antibiotic resistance is what economists call market failure. The cost of bringing one antimicrobial drug to market is between £750m and £1.2bn. Yet the income that brings to a Big Pharma company – for a drug which most people will use only once or twice a year – is small compared to what they can earn from other drugs.

For a start doctors will hold the newest and most potent antibiotics in reserve, for when all else fails, so new drugs are used even less often. By contrast, a medicine such as anti-cholesterol statins, which millions use every day, brings cash in truckloads. So do drugs for which firms can charge massive amounts per dose. A new highly effective treatment for deadly hepatitis C, called Sofosbuvir, is currently $84,000 (£49,000) for a 12-week course in the United States.

This is why no new class of antibiotic has reached the market since 1987. Big Pharma prefers more lucrative areas of activity. In 1990 there were almost 20 antibiotic research and development programmes among the bigger drug companies; today, according to the Infectious Diseases Society of America, there are only a handful. Drug giants Pfizer, Eli Lilly and Bristol-Myers Squibb have switched their focus to cancer and chronic diseases, where drugs command higher prices and are taken for longer. AstraZeneca recently said it would put less money into the activity. Only the Swiss firm Roche has a new offering in development.

The public good demands a new generation of antibiotics. But the market is not providing that. It is not the only area of market failure. There is more money to be made from a drug that allows rich fat people to eat without putting on weight than there is in finding a vaccine for malaria which kills mainly poor people in Africa. GlaxoSmithKline is working on an exciting malaria vaccine called RTS,S but only with a $200m grant from the world's biggest philanthropist, Bill Gates.

The hard truth, which even a free-marketeer such as Cameron has had to confront, is that there are some areas in life where the solutions of the market are nasty, brutish and short term-ist. The common good requires something more than a narrow maximisation of share-holder profit. New models have to be found to draw businesses into a wider social responsibility.

O'Neill will probably say that the National Health Service should pay more for antibiotics on the grounds that though you might only take the drug for a couple of weeks it could extend your life by 50 years. But he also needs to discover mechanisms to create partnerships and greater information-sharing between companies, academic researchers, doctors and regulators. He needs to multiply schemes like the EU's Innovative Medicines Initiative, the Path Malaria Vaccine Initiative or GSK's "open innovation" research-sharing strategy on neglected tropical diseases.

There are things that others can do. Medical professionals could get back to basics; antibiotic-resistant staphylococcus infections in hospitals have been cut by a return to vigilant hand-washing. Consumers could start a campaign to identify and boycott meat which has been plumped up with antibiotics. Governments could find much more cash for relevant university research.

But none of this will be to any avail if the O'Neill commission does not find new business models for the production of antibiotics and other socially essential medicines. Over to you, Jim. We are in a war against microbes, and at present the microbes are winning. A post-antibiotic age is too apocalyptic to contemplate.

Paul Vallely is visiting professor of public ethics at the University of Chester

React Now

Latest stories from i100
Have you tried new the Independent Digital Edition apps?
iJobs Job Widget
iJobs General

Selby Jennings: VP/SVP Credit Quant- NY- Investment Bank

Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...

Ashdown Group: Senior Marketing Executive- City of London, Old Street

£40000 - £43000 per annum + benefits: Ashdown Group: Senior Marketing Executiv...

Ashdown Group: Marketing Manager

£40000 - £43000 per annum + benefits: Ashdown Group: An international organisa...

Ashdown Group: Internal Recruiter -Rugby, Warwickshire

£25000 - £30000 per annum: Ashdown Group: Internal Recruiter -Rugby, Warwicksh...

Day In a Page

Read Next
The Queen spoke of respect for all cultures and faiths in her Christmas message  

Decoding the Queen's speech: Was Her Majesty taking a swipe at Ukip?

Jane Merrick
Iraqi soldiers trained by the US were routed by IS’s smaller force  

War with Isis: The West needs more than a White Knight

Patrick Cockburn
War with Isis: The West needs more than a White Knight

The West needs more than a White Knight

Despite billions spent on weapons, the US has not been able to counter Isis's gruesome tactics, says Patrick Cockburn
Return to Helmand: Private Davey Graham recalls the day he was shot by the Taliban

'The day I was shot by the Taliban'

Private Davey Graham was shot five times during an ambush in 2007 - it was the first, controversial photograph to show the dangers our soldiers faced in Helmand province
Revealed: the best and worst airlines for delays

Revealed: the best and worst airlines for delays

Many flyers are failing to claim compensation to which they are entitled, a new survey has found
The stories that defined 2014: From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions

The stories that defined 2014

From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions
Stoke-on-Trent becomes first British city to be classified as 'disaster resilient' by the United Nations

Disaster looming? Now you know where to head...

Which British city has become the first to be awarded special 'resilience' status by the UN?
Finally, a diet that works: Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced

Finally, a diet that works

Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced
Say it with... lyrics: The power of song was never greater, according to our internet searches

Say it with... lyrics

The power of song was never greater, according to our internet searches
Professor Danielle George: On a mission to bring back the art of 'thinkering'

The joys of 'thinkering'

Professor Danielle George on why we have to nurture tomorrow's scientists today
Monique Roffey: The author on father figures, the nation's narcissism and New Year reflections

Monique Roffey interview

The author on father figures, the nation's narcissism and New Year reflections
Introducing my anti-heroes of 2014

Introducing my anti-heroes of 2014

Their outrageousness and originality makes the world a bit more interesting, says Ellen E Jones
DJ Taylor: Good taste? It's all a matter of timing...

Good taste? It's all a matter of timing...

It has been hard to form generally accepted cultural standards since the middle of the 19th century – and the disintegration is only going to accelerate, says DJ Taylor
Olivia Jacobs & Ben Caplan: 'Ben thought the play was called 'Christian Love'. It was 'Christie in Love' - about a necrophiliac serial killer'

How we met

Olivia Jacobs and Ben Caplan
Bill Granger recipes: Our chef's breakfasts will revitalise you in time for the New Year

Bill Granger's healthy breakfasts

Our chef's healthy recipes are perfect if you've overindulged during the festive season
Transfer guide: From Arsenal to West Ham - what does your club need in the January transfer window?

Who does your club need in the transfer window?

Most Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
The Last Word: From aliens at FA to yak’s milk in the Tour, here’s to 2015

Michael Calvin's Last Word

From aliens at FA to yak’s milk in the Tour, here’s to 2015